title: Systemic therapy for inoperable and metastatic basal cell cancer.
abstract: Cutaneous basal cell carcinoma (BCC) is the most common human malignancy. The majority of cases are cured with local therapies and advanced disease is quite rare. However, locally advanced (inoperable) and metastatic basal cell carcinoma may occur more often than previously thought. Surgery, and other local therapies, is the primary treatment for BCC. However, some resections can be extensive and carry significant morbidity or disfigurement. The prognosis for locally advanced and metastatic BCC is quite poor, and cytotoxic chemotherapies offer limited benefit. Aberrations in the sonic hedgehog (HH) signaling pathway are common in BCC. Novel molecular therapies targeted against this pathway, such as vismodegib (GDC-0449), have shown dramatic activity in advanced basal cell carcinoma. The role of these in nevoid basal cell carcinoma syndrome (Gorlin) syndrome is still under investigation. However, systemic therapies are not curative and require long-term treatment and should not be used in place of curative procedures. Evaluation by experienced physicians and/or by a multidisciplinary tumor board for possible curative/definitive surgery with or without radiation is recommended before initiation of systemic therapy. Clinical trial enrollment also is recommended. Comorbid conditions as well as social circumstances may be factors when deciding on an optimal therapy, in particular with oral agents. Patients treated with HH pathway inhibitors require regular physician monitoring to assess for side effects, benefit, and compliance. Patients of child-bearing potential must be strongly counseled regarding the risk of birth defects and need for birth control. Primary and secondary resistance to HH pathway inhibitors is only beginning to be described.
authors.affiliation: Hematology-Oncology, Indiana University Health Simon Cancer Center, 535 Barnhill Drive, RT-473, Indianapolis, IN 46202, USA. lafecher@iu.edu
authors.forename: Leslie A
authors.initials: LA
authors.lastname: Fecher
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D002280:Basal Cell Carcinoma / Q000188:drug therapy / Q000378:metabolism / Q000601:surgery / Q000628:therapy*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D003131:Combined Modality Therapy; D053823:Hedgehog Proteins / Q000378:metabolism; D006801:Humans; D018295:Neoplasms, Basal Cell / Q000188:drug therapy / Q000378:metabolism / Q000601:surgery / Q000628:therapy*; D016032:Randomized Controlled Trials as Topic; D015398:Signal Transduction / Q000187:drug effects; D012878:Skin Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000601:surgery / Q000628:therapy*
chemical_list: D000970:Antineoplastic Agents; D053823:Hedgehog Proteins
references.citation: Eur J Cancer. 2001 Jan;37(2):251-9
references.pmid: 11166154
references.citation: Cancer. 1994 Jan 15;73(2):328-35
references.pmid: 8293396
references.citation: Cochrane Database Syst Rev. 2007 Jan 24;(1):CD003412
references.pmid: 17253489
references.citation: Br J Dermatol. 1992 Aug;127(2):164-7
references.pmid: 1390146
references.citation: J Cancer. 2012;3:257-61
references.pmid: 22712026
references.citation: Medicine (Baltimore). 1987 Mar;66(2):98-113
references.pmid: 3547011
references.citation: N Engl J Med. 2009 Sep 17;361(12):1164-72
references.pmid: 19726763
references.citation: Arch Dermatol. 2012 Nov;148(11):1324-5
references.pmid: 22910979
references.citation: Onco Targets Ther. 2012;5:47-58
references.pmid: 22500124
references.citation: Cancer Res. 1997 Jul 1;57(13):2581-5
references.pmid: 9205058
references.citation: Gynecol Oncol. 2002 Jun;85(3):532-7
references.pmid: 12051887
references.citation: Science. 2009 Oct 23;326(5952):572-4
references.pmid: 19726788
references.citation: Dermatol Clin. 1995 Jan;13(1):113-25
references.pmid: 7712637
references.citation: J Med Imaging Radiat Oncol. 2008 Jun;52(3):278-86
references.pmid: 18477123
references.citation: J Cutan Pathol. 1993 Apr;20(2):137-42
references.pmid: 8320358
references.citation: Arch Dermatol. 1986 Aug;122(8):912-4
references.pmid: 3740875
references.citation: Cancer. 1983 Nov 1;52(9):1583-5
references.pmid: 6684499
references.citation: N Engl J Med. 2012 Jun 7;366(23):2180-8
references.pmid: 22670904
references.citation: N Engl J Med. 2009 Sep 17;361(12):1173-8
references.pmid: 19726761
references.citation: Oncogene. 2001 Nov 22;20(53):7770-8
references.pmid: 11753655
references.citation: Cell. 1996 Jun 14;85(6):841-51
references.pmid: 8681379
references.citation: Clin Cancer Res. 2003 Jan;9(1):228-34
references.pmid: 12538474
references.citation: Br J Dermatol. 2009 Sep;161(3):702-3
references.pmid: 19575727
references.citation: J Dermatol Surg Oncol. 1994 Jul;20(7):490-3
references.pmid: 8034846
references.citation: J Am Acad Dermatol. 2005 Jan;52(1):149-51
references.pmid: 15627099
references.citation: Cancer. 1985 Apr 15;55(8):1629-32
references.pmid: 4038911
references.citation: Clin Cancer Res. 2011 Apr 15;17(8):2502-11
references.pmid: 21300762
references.citation: Proc Natl Acad Sci U S A. 2007 May 15;104(20):8455-60
references.pmid: 17494766
references.citation: Lipids. 1978 Oct;13(10):708-15
references.pmid: 723484
references.citation: J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Mar 15;878(9-10):785-90
references.pmid: 20172765
references.citation: Arch Dermatol. 1991 Aug;127(8):1194-7
references.pmid: 1863078
references.citation: J Natl Cancer Inst. 1996 Dec 18;88(24):1848-53
references.pmid: 8961975
references.citation: Cancer. 1951 Jul;4(4):866-78
references.pmid: 14859207
references.citation: Cancer Cell. 2010 Apr 13;17(4):388-99
references.pmid: 20385363
references.citation: Cell. 1992 Apr 3;69(1):111-7
references.pmid: 1348213
references.citation: J Dermatol Surg Oncol. 1991 Sep;17(9):720-6
references.pmid: 1820764
references.citation: J Invest Dermatol. 2011 Aug;131(8):1735-44
references.pmid: 21430703
references.citation: Cancer Invest. 2006 Jun-Jul;24(4):396-400
references.pmid: 16777692
references.citation: Postgrad Med J. 1980 Apr;56(654):272-3
references.pmid: 6159619
references.citation: Br J Dermatol. 2008 Jun;158(6):1386-8
references.pmid: 18384472
references.citation: N Engl J Med. 2012 Jun 7;366(23):2171-9
references.pmid: 22670903
references.citation: Eur J Cancer. 1990 Jan;26(1):73-7
references.pmid: 2138485
references.citation: Genes Dev. 2002 Nov 1;16(21):2743-8
references.pmid: 12414725
references.citation: J Invest Dermatol. 1998 Jun;110(6):885-8
references.pmid: 9620294
references.citation: Sci Transl Med. 2010 Sep 29;2(51):51ra70
references.pmid: 20881279
references.citation: Nature. 1998 Jan 1;391(6662):90-2
references.pmid: 9422511
references.citation: Cancer Res. 2011 Jan 15;71(2):435-44
references.pmid: 21123452
references.citation: Cancer Metastasis Rev. 2004 Aug-Dec;23(3-4):389-402
references.pmid: 15197337
references.citation: Br J Dermatol. 2005 Jan;152(1):43-51
references.pmid: 15656799
references.citation: Am J Dermatopathol. 2000 Apr;22(2):123-5
references.pmid: 10770431
references.citation: Clin Cancer Res. 2012 Jun 15;18(12):3218-22
references.pmid: 22679179
references.citation: Br J Dermatol. 1995 Nov;133(5):737-41
references.pmid: 8555026
references.citation: J R Soc Med. 1997 Jul;90(7):371-4
references.pmid: 9290417
references.citation: J Dermatol Surg Oncol. 1992 Jun;18(6):471-6
references.pmid: 1592998
references.citation: Australas J Dermatol. 1973 Apr;14(1):53
references.pmid: 4753676
references.citation: Dermatol Surg. 2012 Oct;38(10):1622-30
references.pmid: 22805312
references.citation: Eur J Dermatol. 2012 May-Jun;22(3):299-309
references.pmid: 22391625
references.citation: Clin Nucl Med. 2007 Jun;32(6):491-2
references.pmid: 17515767
references.citation: Ann Plast Surg. 1990 Feb;24(2):170-5
references.pmid: 2180360
references.citation: J Am Acad Dermatol. 2006 Feb;54(2):189-206; quiz 207-10
references.pmid: 16443048
references.citation: Arch Dermatol. 1977 Sep;113(9):1261-9
references.pmid: 332091
references.citation: ANZ J Surg. 2004 Aug;74(8):704-5
references.pmid: 15315581
references.citation: Arch Dermatol. 1995 Feb;131(2):157-63
references.pmid: 7857111
references.citation: J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
references.pmid: 10655437
references.citation: Bioorg Med Chem Lett. 2009 Oct 1;19(19):5576-81
references.pmid: 19716296
references.citation: J Am Acad Dermatol. 1991 May;24(5 Pt 1):715-9
references.pmid: 1869642
references.citation: Int J Dermatol. 2005 Jan;44(1):54-6
references.pmid: 15663663
references.citation: Cancer Treat Rep. 1978 Oct;62(10):1553-5
references.pmid: 361227
references.citation: J Clin Oncol. 2012 May 10;30(14):1588-93
references.pmid: 22370316
references.citation: J Eur Acad Dermatol Venereol. 2012 Aug;26(8):942-52
references.pmid: 22211959
references.citation: J Dermatol Surg Oncol. 1991 Sep;17(9):713-8
references.pmid: 1890243
references.citation: Acta Oncol. 1996;35(6):677-82
references.pmid: 8938213
references.citation: J Am Acad Dermatol. 2011 Jun;64(6):1051-9
references.pmid: 21255868
references.citation: J Clin Oncol. 1990 Feb;8(2):342-6
references.pmid: 2405109
references.citation: Australas J Dermatol. 1985 Dec;26(3):121-4
references.pmid: 3835954
references.citation: Arch Dermatol. 1990 Dec;126(12):1660
references.pmid: 2256701
references.citation: Dermatol Surg. 2012 Nov;38(11):1863-6
references.pmid: 22805146
references.citation: J Dermatol Surg Oncol. 1992 Jul;18(7):549-54
references.pmid: 1624628
references.citation: J Am Acad Dermatol. 1984 Jun;10(6):1043-60
references.pmid: 6736323
references.citation: Arch Pathol Lab Med. 2006 Jan;130(1):45-51
references.pmid: 16390237
references.citation: Science. 1996 Jun 14;272(5268):1668-71
references.pmid: 8658145
references.citation: N Engl J Med. 2005 Nov 24;353(21):2262-9
references.pmid: 16306523
references.citation: Cancer. 1980 Aug 15;46(4):748-57
references.pmid: 7397637
references.citation: Arch Dermatol. 2010 Mar;146(3):283-7
references.pmid: 20231499